mHealth Family Self-Management
NCT03533049 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 67
Last updated 2020-07-09
Summary
This innovative research will address a gap in the literature involving the evaluation of the impact of an individualized family-centered mHealth application to enhance daily post-discharge communication following pediatric transplant. This proposal lays the foundation for future research with myFAMI (self-management intervention) at multiple pediatric transplant centers and builds the science from which to consider post discharge monitoring and decrease cost of care in other pediatric chronic illness populations.
Conditions
- Transplantation
- Pediatric ALL
Interventions
- OTHER
-
myFAMI
Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
Medical College of Wisconsin
lead OTHER
Principal Investigators
-
Stacee Lerret, PhD · Medical College of Wisconsin
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- SINGLE_GROUP
Eligibility
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-10-01
- Primary Completion
- 2020-04-01
- Completion
- 2020-05-01
Countries
- United States
Study Locations
More Related Trials
-
Self-Management for Youth and Families Living With SCD - SMYLS
NCT03585543 ·Status: COMPLETED ·Phase: NA
-
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
NCT00566696 ·Status: COMPLETED ·Phase: PHASE2
-
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
NCT00799461 ·Status: COMPLETED ·Phase: PHASE3
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03579875 ·Status: RECRUITING ·Phase: PHASE2
-
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
NCT00005641 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
NCT00014469 ·Status: COMPLETED ·Phase: PHASE2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia
NCT00005891 ·Status: COMPLETED ·Phase: NA
-
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
NCT00013533 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
NCT05293509 ·Status: WITHDRAWN ·Phase: PHASE2
-
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
NCT02793544 ·Status: COMPLETED ·Phase: PHASE2
-
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
NCT00368355 ·Status: COMPLETED ·Phase: PHASE2
-
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
NCT01427881 ·Status: COMPLETED ·Phase: PHASE2
-
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
NCT00253552 ·Status: TERMINATED ·Phase: NA
-
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
NCT00553098 ·Status: COMPLETED ·Phase: PHASE2
-
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
NCT03849651 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
NCT01349101 ·Status: COMPLETED ·Phase: PHASE2
-
A Pharmacokinetic Study of Melphalan in Children
NCT02390544 ·Status: COMPLETED ·Phase: PHASE1
-
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
NCT00005797 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia
NCT00005892 ·Status: COMPLETED ·Phase: NA
-
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
NCT04151706 ·Status: COMPLETED ·Phase: PHASE2
-
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
NCT00775632 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
NCT01044745 ·Status: TERMINATED ·Phase: PHASE2
-
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
NCT06926595 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00005092 ·Status: COMPLETED ·Phase: PHASE1